icon-    folder.gif   Conference Reports for NATAP  
  The 21st Conference of the Asian Pacific Association for the Study of the Liver
APASL Feb 17-20, 2011
Bangkok, Thailand
Back grey_arrow_rt.gif
Telaprevir-based Therapy in Genotype 1 Hepatitis C Virus-infected Patients with Prior Null Response, Partial Response or Relapse to Peginterferon/Ribavirin: REALIZE Trial Final Results
  Reported by Jules Levin
Presented at APASL Feb 17-20, 2011 Bangkok, Thailand The 21st Conference of the Asian Pacific Association for the Study of the Liver
Graham R Foster,1 Stefan Zeuzem,2 Pietro Andreone,3 Stanislas Pol,4 Eric Lawitz,5 Moises Diago,6 Stuart Roberts,7 Roberto Focaccia,8 Zobair Younossi,9 Andrzej Horban,10 Rolf Van Heeswijk,11 Sandra De Meyer,11 Don Luo,12 Gaston Picchio,12 Maria Beumont11
1Queen Mary University of London, Institute of Cell and Molecular Science, London, UK; 2Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany; 3Universita di Bologna, Bologna, Italy; 4Universite Paris Descartes, INSERM Unite 567, and Assistance Publique-Hopitaux de Paris, Cochin Hospital Paris, France; 5Alamo Medical Research, San Antonio, TX, USA; 6Hospital General de Valencia, Valencia, Spain; 7Department of Gastroenterology, Alfred Hospital, Melbourne, Australia; 8Emilio Ribas Infectious Diseases Institute, Sao Paulo, Brazil; 9Center for Liver Disease, Inova Fairfax Hospital, Falls Church, VA,USA; 10Medical University of Warsaw, Wolska, Warsaw, Poland; 11Tibotec BVBA, Beerse, Belgium; 12Tibotec Inc., Titusville, NJ, USA
REALIZE update will be presented at EASL in April 2011.